Canevari S相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Anti-PSMA (124)I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle

抗PSMA (124)I-scFvD2B作为一种新型免疫PET工具用于前列腺癌：临床前原理验证

期刊:Journal of Experimental & Clinical Cancer Research

影响因子:12.8

doi:10.1186/s13046-019-1325-6

Frigerio, B; Morlino, S; Luison, E; Seregni, E; Lorenzoni, A; Satta, A; Valdagni, R; Bogni, A; Chiesa, C; Mira, M; Canevari, S; Alessi, A; Figini, M

免疫/内分泌

发表日期：2019

文献求助收藏

An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE

一种具有免疫学意义的啮齿动物模型证实了使用肿瘤特异性IgE进行治疗的安全性。

影响因子:12

doi:10.1111/all.13455

Josephs, D H; Nakamura, M; Bax, H J; Dodev, T S; Muirhead, G; Saul, L; Karagiannis, P; Ilieva, K M; Crescioli, S; Gazinska, P; Woodman, N; Lombardelli, C; Kareemaghay, S; Selkirk, C; Lentfer, H; Barton, C; Canevari, S; Figini, M; Downes, N; Dombrowicz, D; Corrigan, C J; Nestle, F O; Jones, P S; Gould, H J; Blower, P J; Tsoka, S; Spicer, J F; Karagiannis, S N

免疫/内分泌

发表日期：2018

文献求助收藏

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

通过共同靶向人类黑色素瘤中的致癌和死亡受体通路，发挥协同抗肿瘤活性并抑制血管生成

期刊:Cell Death & Disease

影响因子:9.6

doi:10.1038/cddis.2014.410

Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, Bersani I, Nicolini G, Canevari S, Carlo-Stella C, Gianni A M, Mortarini R, Anichini A

发表日期：2014

文献求助收藏

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer

胆碱激酶-α通过调节细胞侵袭性和药物敏感性，是卵巢癌潜在的药物靶点。

期刊:British Journal of Cancer

影响因子:6.8

doi:10.1038/bjc.2013.729

Granata, A; Nicoletti, R; Tinaglia, V; De Cecco, L; Pisanu, M E; Ricci, A; Podo, F; Canevari, S; Iorio, E; Bagnoli, M; Mezzanzanica, D

细胞生物学

发表日期：2014

文献求助收藏

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy

利用磁共振成像、体外和体内磁共振波谱法监测HER2(+)卵巢癌模型对细胞抑制剂顺铂的反应

期刊:British Journal of Cancer

影响因子:6.8

doi:10.1038/bjc.2013.758

Pisanu, M E; Ricci, A; Paris, L; Surrentino, E; Liliac, L; Bagnoli, M; Canevari, S; Mezzanzanica, D; Podo, F; Iorio, E; Canese, R

细胞生物学

发表日期：2014

文献求助收藏

Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line

芬瑞替尼诱导的耐药性卵巢肿瘤细胞系中药物蓄积和肿瘤侵袭性标志物表达降低

期刊:British Journal of Cancer

影响因子:6.8

doi:10.1054/bjoc.2001.1826

Appierto, V; Cavadini, E; Pergolizzi, R; Cleris, L; Lotan, R; Canevari, S; Formelli, F

细胞生物学

发表日期：2001

文献求助收藏

Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1

开发一种新型疫苗制剂，以增强肿瘤相关抗原CaMBr1的免疫原性。

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s002620000113

Perico, M E; Mezzanzanica, D; Luison, E; Alberti, P; Panza, L; Russo, G; Canevari, S

免疫/内分泌

发表日期：2000

文献求助收藏

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity

对亲和素进行生化修饰可以改善其药代动力学和生物分布，并降低免疫原性。

期刊:British Journal of Cancer

影响因子:6.8

doi:10.1038/bjc.1998.463

Chinol, M; Casalini, P; Maggiolo, M; Canevari, S; Omodeo, E S; Caliceti, P; Veronese, F M; Cremonesi, M; Chiolerio, F; Nardone, E; Siccardi, A G; Paganelli, G

免疫/内分泌

发表日期：1998

文献求助收藏

Approaches to implement bispecific antibody treatment of ovarian carcinoma

卵巢癌双特异性抗体治疗的实施方法

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s002620050429

Canevari, S; Mezzanzanica, D; Mazzoni, A; Negri, D R; Figini, M; Ramakrishna, V; Bolis, G; Colnaghi, M I

发表日期：1997

文献求助收藏

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation

抗CD3单克隆抗体（mAb）触发T细胞的效率及其在双特异性mAb生成中的潜在应用价值

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s002620050381

Jacobs, N; Mazzoni, A; Mezzanzanica, D; Negri, D R; Valota, O; Colnaghi, M I; Moutschen, M P; Boniver, J; Canevari, S

单克隆抗体

细胞生物学

免疫/内分泌

发表日期：1997

文献求助收藏